DiaMedica Announces Non-Brokered Private Placement

MINNEAPOLIS, MINNESOTA--(Marketwired - Feb. 27, 2015) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA), announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered private placement of up to 6,000,000 common shares in the capital of the Company at an issue price of $0.10 per common share for gross proceeds of up to $600,000 (the "Offering") based on indications of interest. Insider participation is also anticipated from management and members of the board of directors of the Company. All of the common shares issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date.

The Offering is being offered on a non-brokered private placement basis to accredited investors. The Company may pay finder's fees in accordance with the rules and policies of the TSX Venture Exchange ("TSXV"). The Offering remains subject to the approval of the TSXV. The proceeds will be used by DiaMedica to support development with DM199 for the treatment of vascular diseases and for other working capital purposes.

The Offering is scheduled to close on or about March 6, 2015, subject to regulatory approvals.

About DiaMedica

DiaMedica is a publicly traded (TSX VENTURE:DMA) development stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat vascular and metabolic diseases. DiaMedica's lead product, DM199, is recombinant human tissue kallikrein-1 protein (rhKLK1). DiaMedica's common shares are listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the size and price of the Offering, the Company's objectives, goals, future plans and statements regarding the Offering and the use of proceeds therefrom, the expected closing date of the Offering and obtaining Exchange approval for the Offering. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: the need to satisfy regulatory and legal requirements with respect to the proposed Offering; uncertainties associated with satisfying all remaining contractual obligations of the Phase II study and DM199 in patients with type 2 diabetes; uncertainties associated with the Offering size and price of Units; uncertainties in obtaining listing approval of the Common Shares from the Exchange; changes in equity markets and inflation; and the additional risk factors described in detail in the Prospectus and DiaMedica's other filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.